Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
View Patent ↗A powdery preparation for transmucosal administration comprising a medicine of high molecular weight, a cationic polymer and, as needed, a viscous polymer, further comprising an effective amount of a basic amino acid. The powdery preparation for transmucosal administration has an improved storage stability for the medicine of high molecular weight while maintaining an improved mucosal absorption of the medicine.
1. A powdery preparation for transmucosal administration with an improved storage stability, comprising (i) a medicine of high molecular weight, (ii) a cationic polymer, and (iii) an effective amount of at least one basic amino acid or its pharmaceutically acceptable salt or derivative that improves the storage stability of the preparation, wherein (a) the cationic polymer is an aminoalkyl methacrylate copolymer, (b) the basic amino acid or its pharmaceutically acceptable salt or derivative thereof is an optically active or inactive histidine or arginine, and (c) the storage stability is improved so that the content of the medicine is not less than 93% when analyzed by HPLC in a storage test at 50° C. for two weeks' storage, based on the value of 100% at the initial point.
2. The preparation according to claim 1 , wherein the basic amino acid or its salt is optically active or inactive histidine, or a pharmaceutically acceptable salt thereof.
3. The preparation according to claim 1 , wherein the content of the medicine of high molecular weight is not less than 96% when analysed by HPLC, in a storage test at 50° C. for two weeks' storage, based on the value of 100% at the initial point.
4. The preparation according to claim 1 , further comprising a viscous polymer.
5. The preparation according to claim 4 , wherein the viscous polymer is hydroxypropyl methylcellulose.
6. The preparation according to claim 1 , wherein the medicine of high molecular weight is bioactive peptide or protein.
7. The preparation according to claim 6 , wherein the bioactive peptide or protein is a granulocyte colony-stimulating factor.
8. The preparation according to claim 1 , wherein the preparation is adapted for intranasal administration.
9. The preparation according to claim 1 , further comprising an excipient.
10. The preparation of claim 1 , wherein the effective amount of the basic amino acid or its salt or derivative thereof is from 0.1 to 10.0 W/W %.
11. The preparation of claim 1 , wherein the effective amount of the basic amino acid or its salt or derivative thereof is from 0.5 to 5.0 W/W %.